Societe Generale Effekten (S29031) Trades

Immunic Therapeutics Chief Scientific Officer Dr. Hella Kohlhof joined Steve Darling from Proactive to discuss the company’s progress in developing vidofludimus calcium, a novel treatment designed to combat multiple sclerosis (MS) through a unique dual mode of action. The drug offers neuroprotection, anti-inflammatory effects, and antiviral benefits, addressing key aspects of MS pathology. Dr. Kohlhof emphasized the urgent need for therapies that prevent disability progression in MS patients, helping them maintain independence for as long as possible. She explained that vidofludimus calcium achieves this by activating Nurr1 to promote neuroprotection while simultaneously inhibiting DHODH, reducing inflammation and Epstein-Barr virus (EBV) reactivation—both believed to play a role in MS development and progression. A major milestone for Immunic Inc. is approaching, with the phase 2 CALLIPER trial readout expected in April 2025. This study aims to confirm the drug’s neuroprotective effects, positioning it as a potential disease-modifying treatment for MS. Dr. Kohlhof also highlighted vidofludimus calcium’s strong safety and tolerability profile, noting that it is a once-daily oral tablet that requires no treatment monitoring, making it a convenient option for patients. Looking ahead, Immunic is also advancing phase 3 ENSURE trials for relapsing MS, expected to complete in 2026. With limited treatment options for progressive MS, Dr. Kohlhof underscored the high unmet medical need and the potential impact of vidofludimus calcium on improving patient outcomes worldwide. #proactiveinvestors #immunicinc #nasdaq #imux #MSResearch #VidofludimusCalcium #Neuroprotection #ImmunicInc #MSAwareness #CALLIPERTrial #MSBreakthrough #MSDisability #ClinicalTrials

New Era Helium CEO Will Gray joined Steve Darling from Proactive to outline the company’s strategic shift toward maximizing the value of its helium and natural gas assets in the Permian Basin to support the rapidly growing AI-driven economy. The company is positioning itself as a key player in behind-the-meter power generation, leveraging its resources to fuel high-performance computing and AI data centers. The company confirmed it remains on track to meet key production milestones while exploring an integrated energy strategy. Since 95% of the world’s helium is found in association with natural gas, the company sees a unique opportunity to directly contribute to the AI industry’s expanding power needs. Rather than selling natural gas as a commodity, New Era plans to utilize its Pecos Slope Gas Field to generate up to 70 megawatts (MW) of electricity for at least 20 years, supporting the rising demand for AI computing power. As part of this transition, the company’s joint venture, Texas Critical Data Centers, has signed a non-binding letter of intent to acquire land in Texas for a planned 250MW net-zero AI and high-performance computing center. This move aligns with increasing domestic demand for helium in semiconductor manufacturing and AI applications, further accelerated by the CHIPS and Science Act. New Era Helium anticipates providing a formal update on its Pecos Slope processing plant soon, signaling further progress in its energy-focused strategy. #proactiveinvestors #neweraheliuminc #nasdaq #nehc #oil #gas #perimianbasin #HeliumProduction #DataCenters #CarbonCapture #AI #Semiconductors #EnergyInnovation #NaturalGas #TechGrowth #SustainableEnergy

GoviEx Uranium CEO Daniel Major talked with Proactive's Stephen Gunnion about the company’s latest milestone—the completion and filing of the feasibility study for its Muntanga Uranium Project in Zambia. Major explained that the study underscores the project's simplicity, highlighting its open-pit heap leaching operation, low technical risk, and strong economics. GoviEx is targeting production by 2028, with financial preparations already in progress. The company has appointed Endeavor Financial to lead the debt financing process and has begun outreach to potential lenders. Meanwhile, environmental approvals are expected by year-end, paving the way for construction. Discussing uranium market dynamics, Major pointed to a growing supply deficit and increasing demand from utilities. Despite market uncertainties, term contracts remain strong at around $80 per pound. He also noted shifting supply chains, with African uranium playing a more prominent role due to restrictions on Russian and Kazakh supply. "The market needs these projects," Major stated. "GoviEx with Muntanga is one of those projects that can come in and support and fill that gap." Watch the full interview for more insights. Don’t forget to like the video, subscribe to our channel, and turn on notifications for future updates. #GoviExUranium #UraniumMining #MuntangaProject #ZambiaMining #NuclearEnergy #UraniumMarket #MiningStocks #EnergyTransition #UraniumSupply #Investing

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection